Partial, but not complete, tumor-debulking surgery promotes protective antitumor memory when combined with chemotherapy and adjuvant immunotherapy

Cancer Research

Volumn 65, Issue 17, 2005, Pages 7580-7584

  Broomfield, Steve ^a   Currie, Andrew ^a   Van Der Most, Robbert G ^a   Brown, Matthew ^a   Van Bruggen, Ivonne ^a   Robinson, Bruce W S ^a   Lake, Richard A ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; FGK 45; GEMCITABINE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CD40; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER SURGERY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; IMMUNOLOGICAL MEMORY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR CELL;

ANIMALS; ANTIBODIES; ANTIGENS, CD40; ANTIMETABOLITES, ANTINEOPLASTIC; CELL LINE, TUMOR; CHEMOTHERAPY, ADJUVANT; DEOXYCYTIDINE; IMMUNIZATION, PASSIVE; IMMUNOLOGIC MEMORY; MESOTHELIOMA; MICE; MICE, INBRED BALB C;

EID: 24744458859     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-0328     Document Type: Article

References (19)

1. Davis MR, Manning LS, Whitaker D, Garlepp MJ, Robinson BW. Establishment of a murine model of malignant mesothelioma. Int J Cancer 1992;52:881-6.
2. Marzo AL, Lake RA, Robinson BWS, Scott B. T cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors. Cancer Res 1999;59:1071-9.
3. Nowak AK, Robinson BW, Lake RA. Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy. Cancer Res 2002;62:2353-8.
4. Stumbles PA, Himbeck R, Frelinger JA, Collins EJ, Lake RA, Robinson BW. Cutting Edge: tumor-specific CTL are constitutively cross-armed in draining lymph nodes and transiently disseminate to mediate tumor regression following systemic CD40 activation. J Immunol 2004;173:5923-8.
5. Gilboa E. The promise of cancer vaccines. Nat Rev Cancer 2004;4:401-11.
6. Nowak AK, Robinson BW, Lake RA. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res 2003;63:4490-6.
7. Nowak AK, Lake RA, Marzo AL, et al. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol 2003;170:4905-13.
8. Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance. Adv Immunol 2000;74:181-273.
9. Mullen CA, Rowley DA, Schreiber H. Highly immunogenic regressor tumor cells can prevent development of postsurgical tumor immunity. Cell Immunol 1989;119:101-13.
10. Salvadori S, Martinelli G, Zier K. Resection of solid tumors reverses T cell defects and restores protective immunity. J Immunol 2000;164:2214-20.
11. Danna EA, Sinha P, Gilbert M, Clements VK, Pulaski BA, Ostrand-Rosenberg S. Surgical removal of primary tumor reverses tumor-induced immunosuppression despite the presence of metastatic disease. Cancer Res 2004;64:2205-11.
12. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet 2005;366:397-408.
13. Gershon RK, Carter RL, Kondo K. On concomitant immunity in tumour-bearing hamsters. Nature 1967;213:674-6.
14. Turk MJ, Guevara-Patino JA, Rizzuto GA, Engelhorn ME, Houghton AN. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 2004;200:771-82.
15. Kaech SM, Tan JT, Wherry EJ, Konieczny BT, Surh CD, Ahmed R. Selective expression of the interleukin 7 receptor identifies effector CD8 T cells that give rise to long-lived memory cells. Nat Immunol 2003;4:1191-8.
16. + T cells is hampered by persistent systemic antigen, but full functional capacity is regained in an antigen-free environment. J Immunol 2004;172:6074-9.
17. Wherry EJ, Barber DL, Kaech SM, Blattman JN, Ahmed R. Antigen-independent memory CD8 T cells do not develop during chronic viral infection. Proc Natl Acad Sci U S A 2004;101:16004-9.
18. Lanzavecchia A. Immunology. Licence to kill. Nature 1998;393:413-4.
19. Adams AB, Shirasugi N, Jones TR, et al. Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival. J Immunol 2005;174:542-50.